Buy 3 x Patanjali Arogyavardhini Vati – 80 Tablets on ✓ FREE SHIPPING on qualified orders. : Buy patanjali AROGYAVARDHINI VATI 20 gm. from – Lowest Prices, Only Genuine Products, Replacement. Ph.D. Scholar, PG Department of. Dravyaguna Vigyana, National. Institute of Ayurveda, Jaipur, India. Arogyavardhini Vati: A theoritical analysis.

Author: Gozshura Malagor
Country: Switzerland
Language: English (Spanish)
Genre: Love
Published (Last): 26 January 2006
Pages: 361
PDF File Size: 17.87 Mb
ePub File Size: 13.7 Mb
ISBN: 811-1-85612-556-8
Downloads: 99184
Price: Free* [*Free Regsitration Required]
Uploader: Nikogami

Safety and efficacy evaluation of Ayurvedic treatment Arjuna powder and Arogyavardhini Vati in dyslipidemia patients: None, Conflict of Interest: Cardiovascular disease has multifaceted in which dyslipidemia, inflammation, and immunity play an important role.

Arjuna powder and Arogyavardhini Vati used for centuries has potential for combating these factors. Therefore, the objective of this study was to evaluate the safety and efficacy of Ayurvedic treatment Arjuna powder and Arogyavardhini Vati for dyslipidemia patients. Ninety-six patients satisfied inclusion criteria, and signed informed consent and detailed medical history was recorded. Arjuna powder 5 g, BD for 3 weeks and then Arogyavardhini Vati mg, BD for 4 weeks were prescribed to the patients.

The study was completed by 87 patients. The male and female patients were However, raised HDL level was also observed.

In conclusion, the results of the present prospective cohort study showed that Ayurvedic treatment Arjuna powder and Arogyavardhini Vati is arogyavardhinu and effective for dyslipidemia. ArjunaArogyavardhini Vatidyslipidemia, efficacy, safety.

Safety evaluation of an Ayurvedic medicine, Arogyavardhini vati on brain, liver and kidney in rats.

This article has been cited by 1 Systematic Overview of Bacopa monnieri L. How to cite this article: A pilot prospective cohort clinical study. How to cite this URL: Percentage change from the baseline in serum lipid parameters at the end of treatment.


High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TC: Triglyceride Click here to view.

Safety evaluation of liver and kidney of dyslipidemia patients on treatment with Arjuna powder and Arogyavardhini Vati Click here to view. Chaturvedi V, Bhargava B. Health care delivery for coronary heart disease in India-where are we headed?

Am Heart Hosp J ;5: Forecasting vascular disease cases and associated mortality in India. Reports of the National Commission on Macroeconomics and Health.

Ministry of Health and Family Welfare, India, Diabetes Res Clin Pract ; Focus on patients with fatty liver. Gibson K, Rindone JP. Experience with statin use in patients with chronic agogyavardhini C infection.

Safety evaluation of an Ayurvedic medicine, Arogyavardhini vati on brain, liver and kidney in rats.

Am J Cardiol ; Simvastatin in primary biliary cirrhosis: Effects on arogysvardhini lipids and distinct disease markers. A comparison of the efficacy and toxic effects of sustained- VS immediate-release niacin in hypercholesterolemic patients. Long-term efficacy and safety of fenofibrate and a statin in arogyavaddhini treatment of combined hyperlipidemia. Deterioration in renal function associated with fibrate therapy. J Clin Invest ; C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.

Arogyavardhini Vati

Statins and C-reactive protein. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Libby P, Ridker PM. Novel inflammatory markers of coronary risk: Anonymous, Ayurvedic Vatl of India. Antioxidant and hypocholesterolaemic effects of Terminalia Arjuna tree-bark powder: A randomised placebo-controlled trial. J Assoc Physicians India ; Safety evaluation of an Ayurvedic medicine, Arogyavardhini Vati on brain, liver and kidney in rats.

Innate and acquired immunity in atherogenesis. Inhibitory effects of Terminalia Arjuna on platelet activation in vitro in healthy subjects and patients with coronary artery disease.


Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia Arjuna Roxb. Bark against PX- induced hyperlipidemia.

Indian J Exp Biol ; Anti-inflammatory, immunomodulatory and antinociceptive activity of Terminalia Arjuna Roxb bark powder in mice and rats.

Hypolipemic effect of water extracts of Picrorrhiza kurroa in high fat diet treated mouse. Protective effect of picroliv against hydrazine-induced hyperlipidemia and hepatic steatosis in rats.

Drug Chem Toxicol ; Maruthappan V, Shree KS. Hypolipidemic activity of haritaki terminalia chebula in atherogenic diet induced hyperlipidemic rats.

J Adv Pharm Technol Res ;1: Hypolipidemic effect of triphala in experimentally induced hypercholesteremic rats. Effect of Amla fruit Emblica officinalis Gaertn.

Int J Food Sci Nutr ; Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study. Complement Ther Med ; Choleretic effect of picroliv, the hepatoprotective principle of Picrorhiza kurroa. Anila L, Vijayalakshmi NR.

Flavonoids from Emblica officinalis and Mangifera indica-effectiveness for dyslipidemia. Arogyavatdhini and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase.

J Nat Prod ; Effects of the acute phase response on aroggyavardhini concentration and density distribution of plasma lipids and apolipoproteins.

J Lipid Res ; This article has been cited by. Systematic Overview of Bacopa monnieri L.

Journal of Traditional and Complementary Medicine. Evaluating the anti-inflammatory potential of Tectaria cicutaria L.

Related articles Arjuna Arogyavardhini Vati dyslipidemia efficacy safety.

Author: admin